Astragaloside IV inhibits retinal pigment epithelial cell senescence and reduces IL-1β mRNA stability by targeting FTO-mediated m

Si-Wei Wang, Ping Li, Shi-Yu Liu, De-Lian Huang, Si-Jia Zhang, Xi-Xi Zeng, Tian Lan, Kai-Li Mao, Yuan Gao, Yi-Fan Cheng, Qing Shen, Ye-Ping Ruan, Zhu-Jun Mao

School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China; Panvascular Diseases Research Center, the Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou 324000, China. Electronic address: [email protected] of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China; Panvascular Diseases Research Center, the Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou 324000, China. Electronic address: [email protected]. · pubmed

Paper

Abstract

Resistance to senescence in retinal pigment epithelial (RPE) cells can delay the progression of age-related macular degeneration (AMD). However, the mechanisms underlying RPE cell senescence remain inadequately understood, and effective therapeutic strategies are lacking. While astragaloside IV (Ast) has demonstrated anti-aging properties, its specific effects on RPE cell senescence and potential mechanisms are not yet fully clarified.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Astragaloside IV inhibits senescence in retinal pigment epithelial cells by targeting FTO-mediated mRNA stability. The study addresses a mechanism related to cellular senescence, which is a key aspect of aging and age-related diseases, specifically in the context of age-related macular degeneration.

Author of this paper? Send a correction.